Group 1 - The core viewpoint of the investment strategy report highlights the potential new main lines driven by policies and events, emphasizing the role of ETFs as a key investment tool in a "slow bull" market [2] - The report suggests that the 2025 surge in the innovative drug sector is a result of the resonance between policy, industry, demand, and globalization, indicating that "new" assets in the pharmaceutical sector remain a long-term investment direction [4] - The analysis focuses on five key areas for macroeconomic and investment outlooks for 2026, including supply-demand contradictions, price assessments, financial conditions, economic transformation, and overseas stock-bond allocation experiences [7][8] Group 2 - The pharmaceutical industry is expected to see investment opportunities in 2026, with recent adjustments leading to relatively low valuations, which may restart an upward trend in 2026 [4] - The report recommends focusing on hard technology in pharmaceuticals and specific sub-sectors, including innovative drugs (leading BIC and FIC pipelines), innovative medical devices (imaging, high-value consumables, consumer devices), and medical AI [4] - Tuniu's performance dialogue will explore strategies for recovering outbound tourism, including product upgrades, channel optimization, and private domain operations to reshape competitiveness [11]
12月5日热门路演速递 | 政策、医药、宏观、旅游，四维共振前瞻2026
Wind万得·2025-12-04 22:35